Compare American Superconductor Corporation (AMSC) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Superconductor Corporation vs Johnson & Johnson — how do they compare? American Superconductor Corporation trades at $32.44 (market cap $1.56B), while Johnson & Johnson trades at $260.51 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 401.3× American Superconductor Corporation's market cap, and Johnson & Johnson pays a 2.06% dividend while American Superconductor Corporation pays none. Which is the better fit depends on your goals.
| AMSC | JNJ | |
|---|---|---|
Market Cap | $1.56B | $626.09B |
Sector | Technology | Health |
52-Week High | $66.68 | $267.24 |
52-Week Low | $25.95 | $172.78 |
Enterprise Value | $1.42B | $654.37B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMSC trades at $32.28, up 4.16% today, but faces a bearish technical outlook with 14 sell signals versus 3 buys. The company reported strong revenue growth with Q1 2026 sales up 30% to $94.1M (Zacks, Aug 7, 2026) and a record backlog over $400M, though Q2 earnings missed estimates amid margin pressure. Net income margin improved dramatically to 42.56% in 2026 from 2.7% in 2025, but cash flow turned negative with a $60M net outflow in 2026.
The stock presents a mixed opportunity: robust order growth and expanding margins support upside, but high EV/EBITDA (65.73) and technical weakness pose risks. Analyst consensus is bullish (53% Buy), yet investors should watch execution on backlog conversion and margin sustainability amid competitive and cost pressures.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Superconductor Corporation
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
